» Articles » PMID: 28324102

Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota

Abstract

Context: Increasing evidences suggest a correlation between gut and type 1 diabetes (T1D).

Objective: The objective of this study is to evaluate the gut inflammatory profile and microbiota in patients with T1D compared with healthy control (CTRL) subjects and patients with celiac disease (CD) as gut inflammatory disease controls.

Design/setting/participants: The inflammatory status and microbiome composition were evaluated in biopsies of the duodenal mucosa of patients with T1D (n = 19), in patients with CD (n = 19), and CTRL subjects (n = 16) recruited at San Raffaele Scientific Institute, in Milan, Italy, between 2009 and 2015.

Main Outcome Measures: Inflammation was evaluated by gene expression study and immunohistochemistry. Microbiome composition was analyzed by 16S ribosomal RNA gene sequencing.

Results: An increased expression of CCL13, CCL19, CCL22, CCR2, COX2, IL4R, CD68, PTX3, TNFα, and VEGFA was observed in patients with T1D compared with CTRL subjects and patients with CD. Immunohistochemical analysis confirmed T1D-specific inflammatory status compared with healthy and CD control tissues, mainly characterized by the increase of the monocyte/macrophage lineage infiltration. The T1D duodenal mucosal microbiome results were different from the other groups, with an increase in Firmicutes and Firmicutes/Bacteroidetes ratio and a reduction in Proteobacteria and Bacteroidetes. The expression of genes specific for T1D inflammation was associated with the abundance of specific bacteria in the duodenum.

Conclusions: This study shows that duodenal mucosa in T1D presents disease-specific abnormalities in the inflammatory profile and microbiota. Understanding the mechanisms underlying these features is critical to disentangle the complex pathogenesis of T1D and to gain new perspectives for future therapies targeting the intestine.

Citing Articles

Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases: Mechanism basis, clinical application, and potential prospect.

Yi D, Li T, Xiao Y, Zhang X, Hao Q, Zhang F Bioeng Transl Med. 2025; 10(2):e10728.

PMID: 40060755 PMC: 11883108. DOI: 10.1002/btm2.10728.


Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.

Rondanelli M, Borromeo S, Cavioni A, Gasparri C, Gattone I, Genovese E Metabolites. 2025; 15(2).

PMID: 39997751 PMC: 11857149. DOI: 10.3390/metabo15020127.


A Comprehensive Review of the Effects of Diabetes Mellitus on the Gastrointestinal System.

Sattaru K, Thipani Madhu M, Kumar Singh J, Kandi V, Gupta A, Ca J Cureus. 2025; 17(1):e77845.

PMID: 39991373 PMC: 11845257. DOI: 10.7759/cureus.77845.


Intestinal mucosal immunity and type 1 diabetes: Non-negligible communication between gut and pancreas.

Liu R, Zhang J, Chen S, Xiao Y, Hu J, Zhou Z Diabetes Obes Metab. 2024; 27(3):1045-1064.

PMID: 39618164 PMC: 11802406. DOI: 10.1111/dom.16101.


Dietary Protease Supplementation Improved Growth Performance and Nutrients Digestion via Modulating Intestine Barrier, Immunological Response, and Microbiota Composition in Weaned Piglets.

Liu T, Ma W, Wang J, Wei Y, Wang Y, Luo Z Antioxidants (Basel). 2024; 13(7).

PMID: 39061885 PMC: 11273905. DOI: 10.3390/antiox13070816.